A novel fenofibrate-containing composition having equivalent bioavailability, when compared to conventional capsules, is effective in reducing the size of the conventional capsule preparations. The fenofibrate-containing composition comprises the following formula: TABLE-US-00001 (a) fenofibrate 100 parts by weight, (b) a solid surfactant 3 to 4 parts by weight, (c) lactose 1 to 2 parts by weight, and (d) magnesium stearate 1 to 2 parts by weight, in admixture with a binder and a disintegrator, wherein the sum of said binder and said disintegrator is 17 to 20 parts by weight, and the fenofibrate and the solid surfactant are co-micronizates.